Study of direct costs of type 1 diabetes mellitus in Andalusian patients aged 2-16 years
| Autor: | Gabriela Martínez, María del Mar Romero Pérez, Jose Manuel Jiménez Hinojosa, Juan Pedro López Siguero, Marta de Toro, María Ángeles Santos Mata, María del Mar Alonso Montejo, Gustavo Vivas, Pilar Munguira, María Álvarez Casaño, Isabel Leiva Gea, Francisco Macías |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Blood Glucose
Male Pediatrics medicine.medical_specialty Adolescent medicine.medical_treatment 030209 endocrinology & metabolism 03 medical and health sciences Indirect costs 0302 clinical medicine Health care medicine Humans Hypoglycemic Agents Insulin 030212 general & internal medicine Prospective Studies Child Glycated Hemoglobin Type 1 diabetes business.industry medicine.disease Ketoacidosis Diabetes Mellitus Type 1 Sample size determination Spain Metabolic control analysis Child Preschool Observational study Female Health Expenditures business |
| Zdroj: | Endocrinologia, diabetes y nutricion. 66(8) |
| ISSN: | 2530-0180 |
| Popis: | Introduction Type 1 Diabetes Mellitus (DM1) is the second chronic disease and the most frequent endocrine-metabolic disorder in childhood. The objective of this study is to estimate direct cost of DM1 in pediatric patients in Andalusia. Methodology This is a descriptive, multicenter observational study conducted during six months of 2017–2018, based on a sample of 220 patients, from 6 hospitals in Andalusia. Data from demographic and metabolic control variables, use of continuous glucose monitoring systems, average HbA1c, episodes of severe hypoglycaemia and ketoacidosis, comorbidities and complications, as well as direct health costs were collected; including costs of medication, materials, analytical determinations, complementary tests and costs derived from both in-hospital and out-of-hospital healthcare. Results The sample size was 178 patients. The average of diagnosis age was 6 years, and 4.69 (0.29 SD) years of disease evolution. Average HbA1c was 7.06%, 25% had a result above 7.5%. The estimated annual cost per patient was € 4,720.4. The cost derived from insulins (€ 2,212.9) and insulin administration materials and blood glucose monitor (€ 1,518) added the highest cost percentage (79.1%). Conclusion The study has shown a direct cost associated with DM in pediatric age in Andalusia of approximately € 4,700 per patient. Finally, an association between metabolic control, comorbidities or complications and the disease cost has not been detected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect